Silicon Valley Biosystems, or simply SV Bio, joins InVitae, Caris Life Sciences and Foundation Medicine in developing methods for translating genomics data into clinically useful information. The company plans to create a network of labs to take samples, examine broad genomic regions, decode the data and send the results to doctors within a few days. "The coming age of the $1,000 genome has made it possible for physicians to start thinking about whether it's practical to do broader sequencing runs for routine diagnostic purposes," writes Luke Timmerman.

Full Story:

Related Summaries